Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CStone PharmaceuticalsCSPHF +19.43%47 Debt-to-Equity is 0.57 as of Dec. 2025, which is at its 10-year median of 0.57. GuruFocus rates CSPHF with a GF Score™ of 47/100 and a GF Value™ of $0.18 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 968 Biotechnology companies, CStone Pharmaceuticals ranks worse than 78.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CStone Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
CSPHF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.57 Max: 0.98
Current: 0.57
During the past 10 years, the highest Debt-to-Equity Ratio of CStone Pharmaceuticals was 0.98. The lowest was 0.00. And the median was 0.57.
CSPHF's Debt-to-Equity is ranked worse than 78.1% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs CSPHF: 0.57
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CStone Pharmaceuticals Debt-to-Equity Related Terms
CStone Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CStone Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPHF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, CStone Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CStone Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CStone Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CStone Pharmaceuticals (CSPHF) has a Debt-to-Equity of 0.57 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CStone Pharmaceuticals and its competitors. This is near median its historical median of 0.57. According to the industry distribution chart, CStone Pharmaceuticals ranks #756 out of 968 companies in the Biotechnology industry, placing it in the top 78.1%.
Is CStone Pharmaceuticals' Debt-to-Equity too high?
CStone Pharmaceuticals' current Debt-to-Equity of 0.57 is near median its 10-year median of 0.57. The Biotechnology industry median Debt-to-Equity is 0.16. CStone Pharmaceuticals' value of 0.57 is 256.3% above this industry median. Based on the distribution chart, CStone Pharmaceuticals ranks #756 out of 968 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CStone Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CStone Pharmaceuticals ranks #756 out of 968 companies for Debt-to-Equity. This places CStone Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.16. CStone Pharmaceuticals' value of 0.57 is 256.3% above this benchmark. While the company's 10-year median is 0.57 vs. the industry median of 0.16, CStone Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CStone Pharmaceuticals's current Debt-to-Equity of 0.57 is 256.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CStone Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CStone Pharmaceuticals's current Debt-to-Equity is 0.57, which is near median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.18, compared to a current price of $0.71 — trading 294.4% above its estimated fair value. The current Debt-to-Equity is 0.57, which is near median its 10-year median of 0.57 and 256.3% above the Biotechnology industry median of 0.16. CStone Pharmaceuticals' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Debt-to-Equity is 0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?
Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.71 is trading 294.4% above its estimated GF Value™ of $0.18.
GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CSPHF:
Debt-to-Equity: 0.57 (near median its 10-year median of 0.57)
GF Value™: $0.18 vs. price of $0.71 (294.4% above fair value)
Industry Position: 256.3% above the Biotechnology median (#756 of 968)
No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
47GF Score
Get the complete analysis for CSPHF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPHF has been successfully added to your 
